A new phase 2 trial suggests that cryopreserved virus-specific T cells (VSTs) prepared from third-party donors are a safe and effective treatment for recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT) who develop drug-refractory viral infections. Viral infection is a common, life-threatening complication for these patients, and drug treatment can be ineffective or have substantial side-effects.

中文翻译：

---

干细胞移植后即用型T细胞可用于感染

一项新的2期试验表明，由第三方供体制备的冷冻保存的病毒特异性T细胞（VST）对于发生药物难治性病毒感染的同种异体造血干细胞移植（allo-HSCT）受体是一种安全有效的治疗方法。病毒感染是这些患者常见的威胁生命的并发症，药物治疗可能无效或有重大副作用。